For Indian pharma, AI tooling has to clear a higher bar than most sectors: GxP governance and IP protection. Here’s a grounded view of the tools and how to structure them. (dgm implements osFoundry, a separate company’s platform — dgm is an independent integration partner, not osFoundry, and this is not regulatory advice.)
The tool categories
| Use case | What the tools do | GxP/India note |
|---|---|---|
| Drug discovery | Molecular analysis, target prediction | IP protection |
| Clinical trials | Design, site selection, recruitment | Trial-data control |
| Pharmacovigilance | Gen-AI case processing, content | Audit + validation |
| GxP manufacturing | Process optimisation, deviation prediction | Controlled records |
CROs and firms like Indegene apply these, and EY-Parthenon + Microsoft have published enterprise AI-scaling frameworks for Indian pharma.
Tools must clear the GxP bar
In regulated pharma, AI tools must support audit trails, validation, and authorised human review of output before it becomes a controlled record. Following the 2026 FDA warning letter on AI in cGMP documentation (see AI in pharma in India), tools that produce opaque, unreviewed outputs are a compliance risk. Governance and traceability are requirements, not extras.
IP and data sovereignty push toward self-hosting
Pharma handles valuable IP (molecular and trial data) and sensitive personal data, so firms often need to control where AI runs and keep data in-boundary — pushing toward self-hostable, region-controllable deployment rather than sending discovery or trial data to an external cloud. This protects IP and supports DPDP and CDSCO compliance.
Consolidate for consistent governance
Disparate tools with inconsistent audit and validation make GxP compliance harder. An orchestration layer that applies consistent governance across discovery, document and manufacturing AI — and keeps data controlled — is cleaner than scattered subscriptions (see SaaS consolidation).
Where osFoundry fits
osFoundry is the model-neutral, self-hostable layer — it can apply a consistent config, audit and human-review layer across pharma AI workflows, self-hosted for IP and data control. dgm builds the controls; your QA/regulatory team owns GxP/CDSCO determinations. osFoundry is younger with limited independent coverage, so dgm validates fit.
How dgm helps
dgm orchestrates pharma AI on osFoundry with audit trails, human-in-the-loop review and validation, self-hosted for IP and data control. Transparent pricing: $399 assessment, $3,999/month implementation, no per-seat fees (INR approximate; 18% GST for domestic clients). Explore the platform at osFoundry, or talk to dgm about pharma AI tooling.
General information, not regulatory advice. Confirm CDSCO, GxP and FDA obligations with qualified experts before deploying.